The efficacy of phenylephrine might be improved by giving doses higher than that traditionally used (100 μg). This study compared the effects of three initial bolus doses of intravenous phenylephrine; 100 μg (group P100), 125 μg (group P125) and 150 μg (group P150), for the treatment of post-spinal hypotension in patients undergoing elective caesarean delivery. If hypotension was not corrected by this dose, additional boluses of 25 μg were given every minute. Further hypotensive episodes were treated with half the initial bolus dose, followed by 25 μg boluses, as required. Umbilical arterial and venous blood samples were obtained for blood gas analysis and Apgar scores recorded. One hundred and twenty subjects (40 per group) who developed post-spinal hypotension (75%) were included in this randomised, double blind trial. Although systolic blood pressure was higher at certain time-points after 150 μg phenylephrine, there were no statistically significant differences in the effectiveness of the first bolus of phenylephrine to treat hypotension (85%, 95% and 95% in groups P100, P125 and P150, respectively, P=0.215); the additional dose of phenylephrine after the first bolus (P=0.810); the number of additional boluses (P=0.318) or of hypotensive episodes (P=0.118). There were no significant differences in the number of patients developing reactive hypertension or bradycardia, in maternal side-effects or in neonatal outcomes. Although the study may have been underpowered, initial phenylephrine bolus doses of 100 µg, 125 µg and 150 µg did not significantly differ in efficacy to treat post-spinal hypotension in these patients.
Hypotension following spinal anaesthesia in obstetric patients is a very common complication, with an incidence as high as 80% [1] [2] [3] . Unless urgently treated, hypotension may prove harmful to both the foetus and the mother. Foetal effects include decreased uteroplacental blood-flow and impaired oxygenation with hypoxic stress and acidosis; whereas maternal effects include symptoms of low cardiac output such as nausea, vomiting, dizziness and decreased consciousness 4 .
Despite a number of methods being used, vasopressors are the mainstay of management of hypotension associated with spinal anaesthesia 5 . Phenylephrine, a pure alpha agonist, is now established as the first line vasopressor 5 but consensus has not been reached on its optimal use 6 . High doses are reported to cause maternal hypertension and bradycardia, with resulting decrease in cardiac output 6, 7 . Both intravenous infusion and boluses in different doses have been studied 8,9 ; both fixed and variable dose infusions are successful 10, 11 . Prophylactic fixed rate infusions reduce the incidence and severity of maternal hypotension, but result in more reactive hypertension 10 . Prophylactic variable rate infusions, with rescue bolus doses, limit clinician workload and maternal symptoms 11 . Administration by bolus alone does not require an infusion pump, is easy and clinically practical but the optimal dose is not known 12 , with doses of 40 to 100 μg used [12] [13] [14] [15] [16] . Recent studies suggest that the effective dose may be larger 17, 18 . Tanaka et al determined the 95% effective dose (ED 95 ) of phenylephrine, by intermittent intravenous bolus, to prevent post-spinal hypotension and/or nausea during elective caesarean section 17 . Although the largest dose used in the study was 120 μg, the ED 95 was estimated as 159 μg (95% confidence interval, 122 to 371 μg). George et al estimated the 90% effective dose (ED 90 ) of phenylephrine to treat hypotension as 147 μg (95% confidence interval, 98 to 222 μg) 18 and commented that while the traditional bolus dose of 100 μg may be reasonable, the efficacy of phenylephrine may be improved by giving higher doses.
This randomised, controlled trial was planned to compare the effectiveness of three different bolus doses of intravenous phenylephrine for treatment of post-spinal hypotension in patients undergoing elective caesarean delivery under spinal anaesthesia, with secondary outcomes of neonatal Apgar scores, foetal acidosis and maternal complications.
Materials and methods
The study was approved by the institutional ethics committee and written informed consent was obtained from all subjects prior to inclusion in the study. The trial was registered at http://ctri.nic.in (Trial Registration no. CTRI/2011/12/002294). This randomised, double blind study was conducted in American Society of Anesthesiologists Physical Status I or II females with term, uncomplicated, singleton pregnancies, undergoing elective caesarean delivery under spinal anaesthesia. One hundred and twenty subjects who developed hypotension after spinal anaesthesia were randomly allocated to three groups using a draw-of-lots technique. The patients with maternal complications (e.g. diabetes, pregnancy-induced hypertension, cardiovascular disease, cerebrovascular disease), placental complications (e.g. placenta praevia, abruptio placentae), cord complications (e.g. nuchal cord or cord prolapse), foetal malformations, absolute or relative contraindications to spinal anaesthesia (e.g. infection in lumbar area, coagulation abnormalities, autonomic neuropathy, spinal deformities, other neurological diseases and hypovolaemia due to any cause), maternal baseline systolic blood pressure (SBP) less than 100 mmHg or baby birth weight less than 2.5 kg or greater than 4.5 kg were excluded from the study.
The patients were divided into three groups of 40 each, according to the dose of phenylephrine to be used for treatment of hypotension. For randomisation, 120 sealed opaque envelopes (i.e. 40 for each group) were kept in a box, out of which one envelope was drawn and the study drug was prepared accordingly by a person not involved in the study. The patients in groups P100, P125 and P150 received the initial bolus of phenylephrine 100, 125 and 150 μg respectively in a volume of 5 ml.
On the operating table, baseline values for maternal heart rate (HR) and SBP were calculated as an average of three readings in the supine position with left uterine displacement. All patients received an intravenous pre-and co-load of Ringer's Lactate solution 15 ml/kg. Approximately 500 ml was administered before, and the rest given rapidly after, spinal injection. Lumbar puncture was performed in the lateral position by a midline approach at L2-L3 or L3-L4 vertebral interspace using a 25 gauge spinal needle. Hyperbaric 0.5% bupivacaine 2.2 ml, or 2 ml in patients with height less
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Subjects who did not experience postspinal hypotension n=41 than 150 cm, was injected, then the patients were turned supine with left uterine displacement. HR and SBP were recorded per minute until delivery of the baby.
Hypotension was defined as a fall ≥20% below baseline or an absolute value <100 mmHg SBP. The higher of these values was taken as the 'hypotension value'. Reactive hypertension was defined as an increase in SBP >20% from baseline. Bradycardia was defined as a HR <60 beats/minute, however glycopyrrolate 0.2 mg was administered only if bradycardia was associated with hypotension or HR < 50/ minute was associated with SBP <baseline or HR was <45/ minute.
Phenylephrine 100, 125 or 150 μg, depending on group allocation, was diluted to 5 ml with normal saline. Two such syringes with the same dose of phenylephrine (Test Syringes 1 and 2) were kept ready. Another 10 ml syringe containing 25 μg/ml phenylephrine was prepared. When hypotension developed, 5 ml of study drug (Test Syringe 1) was administered. If hypotension was not relieved by this dose, additional boluses of 25 μg phenylephrine from the 10 ml syringe were given every minute until effective. This period from onset to treatment of hypotension was considered as one hypotensive episode. When a second episode of hypotension developed after correction of the first episode, 2.5 ml of study solution from Test Syringe 2 was administered, followed by additional boluses of 25 μg every minute from the 10 ml syringe, if required. In a case of recurrent episodes of hypotension, another test syringe was prepared by the same person who had prepared the test drug earlier. If hypotension did not develop in a case, the envelope for that case was re-sealed and replaced in the box.
The number of patients treated by the first bolus of phenylephrine, the additional amount of phenylephrine required subsequently and the number of additional boluses were calculated. As half of the initial bolus dose (2.5 ml of study solution) was administered for treatment of second and subsequent episodes of hypotension, this was counted as two multiples of 25 μg in group P100, two and half multiples of 25 μg in group P125 and three multiples of 25 μg in group P150, to allow a comparison of the number of additional boluses used. The number of hypotensive episodes and the incidence of reactive hypertension or bradycardia were recorded. The SBP and HR values from onset of hypotension were compared for the three groups for up to six minutes following the onset of hypotension. Samples for umbilical arterial and venous blood gas analysis were obtained from a segment of umbilical cord, double clamped before baby's first breath. Apgar scores were recorded at one and five minutes after birth, as were maternal complications, being a composite of headache, nausea, vomiting and dizziness. Foetal acidosis was defined as umbilical arterial pH <7.2. The sample size calculation was based on the primary outcome of the effectiveness of the phenylephrine bolus. Phenylephrine in a bolus dose of 100 μg has been reported to treat hypotension for 76% of these patients 18 . Considering an increase in success rate by 20% to be clinically significant, 40 patients in each group were required to detect such a difference at 80% power and 5% level of significance. Statistical analysis was performed using SPSS Version 17.0 (IBM, Armonk, NY, USA). The continuous variables were compared among groups by one-way analysis of variance, followed by post hoc analysis using Tukey's test. For qualitative data, either chi-square test or Fisher's exact test was used. P <0.05 was considered statistically significant.
Results
Two hundred and ten patients were screened, of which 161 met the inclusion criteria and agreed to participate. One hundred and twenty subjects who developed post-spinal hypotension (75%) were included in the study and received phenylephrine as per the study protocol ( Figure 1 ). The patient demographic profile, subarachnoid block to delivery and uterine incision to delivery intervals in the three groups were comparable ( Table 1 ).
The haemodynamic parameters are shown in Table 2 . The mean baseline parameters were similar among the groups. Sixteen, 13 and 12 patients (groups P100, P125 and P150, respectively) had repeated episodes of hypotension. The median number of hypotensive episodes was similar across the three groups ( Table 2 ). The first bolus of phenylephrine successfully treated hypotension in 34, 38 and 38 patients in groups P100, P125 and P150, respectively (P >0.05, Table 3 ).
The maximum percentage fall in SBP was calculated for every patient and the mean values in each group did not significantly differ ( Table 2 ). There was no significant difference in the number of patients developing reactive hypertension or bradycardia ( Table 2) .
The SBP and HR values from onset of hypotension were only compared for six minutes because subsequent numbers were not sufficient to provide reliable results. The SBP values did not differ at the first, fourth and sixth minutes after administration of phenylephrine. Group P150 demonstrated higher values than group P100 at the second, third and fifth minutes and group P125 at the second and fifth minutes (P <0.05) ( Figure 2 ). However, groups P100 and P125 had comparable SBP values at all times (P >0.05). No significant intergroup difference was seen in HR (P=0.47) (Figure 3 ). No. of additional 25 μg boluses 0 (0-3) 0 (0-2) 0 (0-2.5) 0.318 Values are mean ± standard deviation, number (%) or median (interquartile range). The phenylephrine requirements are shown in Table 3 . The median number of additional boluses, in terms of 25 μg multiples, was comparable ( Table 3 ). After administration of the first dose, the number of patients requiring additional phenylephrine and the mean requirement of additional phenylephrine for treatment of first and/or subsequent episodes of hypotension was similar across groups ( Table 3 ). In group P100, six patients who were not treated by the first bolus of phenylephrine required an additional bolus of 25 µg each. In group P125, one patient required a further bolus of 25 µg, while another required 50 µg to treat the first episode of hypotension. In group P150, two patients each required a bolus of 25 µg.
The Apgar scores and birth weights were comparable. One neonate from group P100 had an Apgar score of 3 and 7 at the first and fifth minutes respectively, but no acidosis. Due to technical difficulties, umbilical cord blood gas analysis could not be performed in two, four and five subjects in groups P100, P125 and P150 respectively, but umbilical arterial and venous blood gas analyses were comparable ( Table  4 ). Foetal acidosis was found in three, one and two patients in groups P100, P125 and P150 respectively (P=0.870). The Apgar score of the baby in group P125 was 7 and 9 at the first and fifth minutes respectively, while all other babies with acidosis scored 9 and 9.
The incidence of maternal complications did not significantly differ among the groups. Two patients in group P125 and one in group P150 complained of headache (P=0.772). One patient in group P100 and two patients in both groups P125 and P150 experienced nausea and/or vomiting (P=0.772). One patient each in groups P100 and P150 complained of dizziness, associated with hypotension (P=1.00). All symptoms were self-limiting and resolved.
Discussion
Recent studies using an up-down method for dose estimation have calculated phenylephrine bolus doses required for prevention (ED 95 137 µg) 17 and treatment (ED 90 147 µg) 18 of post-spinal hypotension to be higher than the traditionally used dose of 100 µg. This suggested the need for further evaluation of phenylephrine in this higher dose range, both in terms of efficacy and safety. No previous studies in the English language literature compared different doses of phenylephrine in a randomised manner. In this study, although a dose of 150 µg maintained blood pressure at a higher level at certain time-points, it did not appear to improve efficacy in treating hypotension compared with 100 µg. All three doses appeared to be safe and had a similar effect on neonatal outcome.
The efficacy of phenylephrine was assessed using four outcomes, namely the effectiveness of first bolus to treat hypotension, the number of additional boluses and extra phenylephrine required after the first bolus during the study period to treat hypotension and the number of hypotensive episodes. None of these were significantly different between the study groups, with the first bolus dose effectively treating hypotension in the majority of women. Thereafter, it appeared that higher initial bolus doses did not reduce the additional dose of phenylephrine required to manage further episodes of hypotension, nor better maintain maternal haemodynamic stability. There was no apparent advantage to using higher initial maternal doses of phenylephrine.
The maximum percentage fall in SBP was calculated because there was a possibility of higher phenylephrine requirements in patients with a greater fall in blood pressure, but this proved non-significantly different among the groups (P=0.522). Although higher SBP readings were noted at certain time-points in group P150, there was no significant difference at one minute. As the peak rise in blood pressure after intravenous phenylephrine occurs at 30 to 45 seconds 19 , there was again no evidence that a particular dose resulted in a better effect.
The neonatal outcome in terms of Apgar scores and umbilical cord blood gas analysis was similar across all three dosing regimens. Though true foetal acidosis is usually defined as umbili-(/min) Figure 2 : Trends of systolic blood pressure from onset of hypotension. Group P150 versus group P100: P <0.05 at two, three and five minutes. Group P150 versus group P125: P <0.05 at two and five minutes. cal artery pH <7.2, Armstrong et al suggested a pH <7.0 was a better threshold value, because significant adverse outcomes in the neonate are rare if umbilical artery pH is >7.0 or base excess is >-12 mmol/l 20 . In this study, none of the neonates in any of the groups had umbilical artery pH <7.0. The absence of significant differences, also for the incidence of maternal complications, suggests that increasing the dose of phenylephrine had no adverse effect on foetal or maternal outcome. High doses of phenylephrine administered by infusions have been reported to cause hypertension and bradycardia 6, 9, 21, 22 . Cardiac output may also decrease as a result of decreased stroke volume due to marked increase in systemic vascular resistance. Thus, even if higher doses had proved more effective against hypotension, the effect needs to be balanced with the potential for more hypertension and bradycardia with compromised cardiac output. Maternal cardiac output is known to correlate closely with uteroplacental blood flow and foetal oxygen delivery 23 , so administration of phenylephrine in doses large enough to cause hypertension and bradycardia is considered inappropriate 7 . Phenylephrine by bolus injection should result in lower total doses being administered, as compared to prophylactic infusion dosing. As suggested by George et al 18 and Tanaka et al 17 , bolus doses higher than 100 μg may be more reliably effective. In the current study, some higher SBP values were seen after 150 μg, but the incidence of hypertension and bradycardia was not significantly different. It is possible that this study lacked sufficient power to show differences in efficacy and also in side-effects.
We found that phenylephrine 100 μg showed reasonable efficacy to treat hypotension and was associated with good neonatal and maternal outcomes. An increase in dose beyond 100 μg did not appear to improve effectiveness against postspinal hypotension. In contrast, George et al 18 found that higher doses had greater efficacy, but limitations included restricting treatment to the first episode of hypotension using a single bolus. Therefore, their results may not be applicable to the treatment of recurrent episodes of hypotension occurring at a later stage. Also the 95% confidence interval in their study ranged over 100 µg, which limited the precision of their calculated dose. Langesaeter and Dyer 24 also opined that the estimated ED 90 18 and ED 95 17 of phenylephrine may be too high to be recommended in routine clinical practice.
Of a total of 120 patients in this study, 40 developed a low HR of <60/minute, although only four required glycopyrrolate. Bradycardia following phenylephrine administration results from a baroreceptor reflex-mediated increase in vagal tone due to rise in arterial pressure 9 . It should be treated only if it is associated with hypotension, because use of vagolytics in the absence of hypotension may result in reactive hypertension 10, 25 .
This study has several limitations. First, the sample size was calculated considering 76% effectiveness of 100 µg phenylephrine to treat hypotension, based on the evidence in the literature 18 . However, we found this dose to be effective in 85% of cases. Hence, a larger number of patients would be required to exclude a statistically significant benefit from a higher dose. Secondly, as not all patients developed hypotension requiring vasopressor treatment, some of the randomisation envelopes were put back in the box used to draw lots. Although the envelopes were resealed before returning to the pool, this method raises the possibility of bias in patient allocation. Lastly, patients having a baseline SBP less than 100 mmHg were excluded from the study, so the results of the study may not be applicable to this group.
To conclude, a phenylephrine bolus dose of 150 µg maintained a higher systolic blood pressure than doses of 100 or 125 µg at certain time-points following administration, but all three doses appeared to have similar efficacy to treat post-spinal hypotension in patients undergoing elective caesarean delivery. Neonatal outcomes and the incidence of maternal complications appeared comparable but these findings require further investigation. On the basis of our findings, phenylephrine bolus doses higher than 100 µg cannot be recommended, but a study with a larger sample size is necessary to confirm our observations. Studies should focus on achieving a balance between efficacy and side-effects of phenylephrine.
